Antonelli Tiziana, Ferraro Luca, Fuxe Kjell, Finetti Simone, Fournier Jacqueline, Tanganelli Sergio, De Mattei Monica, Tomasini Maria Cristina
Department of Clinical and Experimental Medicine, Pharmacology Section, University of Ferrara, Ferrara, Italy.
Cereb Cortex. 2004 Apr;14(4):466-73. doi: 10.1093/cercor/bhh008.
Primary cultures of cortical neurons were employed to investigate the modulatory effects of neurotensin on glutamate excitotoxicity and the possible neuroprotective actions of the neurotensin receptor antagonist SR48692. NT(1-13) and its biologically active fragment NT(8-13) at 10 nM (30 min) increased endogenous glutamate levels. The inactive fragment NT(1-7) (10-100 nM; 30 min) was ineffective. SR48692, applied 20 min before NT and maintained in contact with cells during NT exposure as well as a low calcium medium (from the onset of the experiment) prevented the NT(1-13)-induced increase in extracellular glutamate levels. The addition of NMDA (0.01-10 micro M; 10 min) to the medium concentration-dependently increased extracellular glutamate levels. When 0.1 nM NT(1-13) was added in combination with 0.01 micro M NMDA, in concentrations by themselves ineffective, a significant increase in glutamate levels was observed. SR48692 at 100 nM counteracted the increase in glutamate levels induced by 0.1 nM NT(1-13) plus 0.01 micro M NMDA. The inhibitor of the protein kinase C (PKC) calphostin C (0.1 micro M; 10 min before NT) prevented the increase in glutamate levels induced by the combined treatments. The morphological analysis indicated that 10 nM NT(1-13) enhanced the glutamate (10 min)-induced apoptosis. The peptide was added 30 min prior to glutamate and maintained in contact with cells during the glutamate exposure. The presence of 100 nM SR48692 (20 min before NT) antagonized this effect of NT(1-13). These findings support the view of a pathophysiological role for NT in the cerebral cortex. Thus, under pathological conditions NT by enhancing glutamate outflow and by amplifying the NMDA-mediated glutamate signaling may be involved in increasing the degeneration of cortical neurons.
采用皮质神经元原代培养物来研究神经降压素对谷氨酸兴奋性毒性的调节作用以及神经降压素受体拮抗剂SR48692可能的神经保护作用。10 nM的神经降压素(1-13)[NT(1-13)]及其生物活性片段NT(8-13)(30分钟)可增加内源性谷氨酸水平。无活性片段NT(1-7)(10 - 100 nM;30分钟)则无此作用。在神经降压素处理前20分钟加入SR48692,并在神经降压素作用期间使其与细胞保持接触,同时采用低钙培养基(从实验开始)可防止NT(1-13)诱导的细胞外谷氨酸水平升高。向培养基中添加N-甲基-D-天冬氨酸(NMDA,0.01 - 10 μM;10分钟)可使细胞外谷氨酸水平呈浓度依赖性升高。当将0.1 nM NT(1-13)与本身无作用浓度的0.01 μM NMDA联合添加时,可观察到谷氨酸水平显著升高。100 nM的SR48692可抵消0.1 nM NT(1-13)加0.01 μM NMDA诱导的谷氨酸水平升高。蛋白激酶C(PKC)抑制剂钙泊三醇C(0.1 μM;在神经降压素处理前10分钟)可防止联合处理诱导的谷氨酸水平升高。形态学分析表明,10 nM NT(1-13)可增强谷氨酸(10分钟)诱导的细胞凋亡。该肽在谷氨酸处理前30分钟加入,并在谷氨酸作用期间与细胞保持接触。100 nM SR48692(在神经降压素处理前20分钟)的存在可拮抗NT(1-13)的这一作用。这些发现支持了神经降压素在大脑皮质中具有病理生理作用的观点。因此,在病理条件下,神经降压素通过增强谷氨酸外流以及放大NMDA介导的谷氨酸信号传导,可能参与增加皮质神经元的变性。